Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho Invites Applicants for Development of Diaminopyridine
August 30, 2010
- Anti-IL-6 Receptor Antibody Effective for IBD: NIBIO, Osaka Univ.
August 30, 2010
- Rohto: Sales Down due to Slump of Pollinosis, Metabolic Syndrome-Related Products
August 30, 2010
- Teijin: Maintains Top Market Share for Osteoporosis Drugs
August 30, 2010
- Canakinumab, KW-0761 Designated as Orphan Drugs
August 30, 2010
- Vectibix Fails to Prolong OS in Head and Neck Cancer
August 30, 2010
- Pfizer Applies for Its 1st Generics Aiming at Listing in 2011
August 30, 2010
- Meiji Seika: Sales Up 16.6% Driven by New Drugs
August 30, 2010
- All Applicants Should Be Given Access to Prior Assessment System: JPMA
August 30, 2010
- Terumo: Sales Up 4.9% Driven by Strong Overseas Sales
August 30, 2010
- Fujitsu Aims at 30% Market Share with Cloud Services for Pharma Industry
August 30, 2010
- Asahi Kasei Pharma: Sales Down for Mainstay Products
August 30, 2010
- 80% of Oncologists Conduct KRAS Gene Test: Merck Serono
August 30, 2010
- Miraca HD: Sales Up 10.4% to ¥41.4 Bil.
August 30, 2010
- Torii: Anti-HIV Drug Props Up Business
August 30, 2010
- Korosho to Promote Sharing of Knowhow on Use of Generics
August 30, 2010
- Takara Bio: Gene Engineering Segment Struggles
August 30, 2010
- Yakult: Elplat's Sales Up 31.4%
August 30, 2010
- Sawai: Sales to Dispending Pharmacies Up 59.2%
August 30, 2010
- A&T: Acquisition of ATWill Boosts Sales of In Vitro Diagnostics
August 30, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…